Chinese pharmaceutical companies are trying to keep up with the surge in demand for fever-reducing medicine, as the country grapples with a spike in Covid-19 cases after Beijing ended its strict zero-Covid policy late 2022. Officials say production of paracetamol and ibuprofen has risen to four times as much as early December’s output.